The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 09, 2016

Filed:

Jul. 08, 2014
Applicant:

Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v., München, DE;

Inventors:

Markus Zweckstetter, Goettingen, DE;

Pinar Karpinar, Goettingen, DE;

Christian Griesinger, Goettingen, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); C12N 15/10 (2006.01); C07K 14/47 (2006.01); A01K 67/033 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0275 (2013.01); A01K 67/0336 (2013.01); A01K 67/0339 (2013.01); C07K 14/47 (2013.01); C12N 15/102 (2013.01); A01K 2227/105 (2013.01); A01K 2227/106 (2013.01); A01K 2227/703 (2013.01); A01K 2227/706 (2013.01); A01K 2267/03 (2013.01);
Abstract

The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims.


Find Patent Forward Citations

Loading…